Your browser is no longer supported. Please, upgrade your browser.
HomeNewsScreenerMapsGroupsPortfolioInsiderFuturesForexCryptoBacktestsElite Help
publish chart | save to portfolio | create alert Type: candle | line | advanced | interactive | perf    Timeframe: intraday | daily | weekly | monthly
ADAP Adaptimmune Therapeutics plc monthly Stock Chart
ADAP [NASD]
Adaptimmune Therapeutics plc
Healthcare | Biotechnology | United Kingdom
statements
Index- P/E- EPS (ttm)-1.31 Insider Own0.20% Shs Outstand130.53M Perf Week8.78%
Market Cap372.01M Forward P/E- EPS next Y-1.14 Insider Trans- Shs Float36.16M Perf Month-22.13%
Income-137.20M PEG- EPS next Q-0.25 Inst Own55.60% Short Float1.30% Perf Quarter106.52%
Sales1.10M P/S338.19 EPS this Y-33.20% Inst Trans6.05% Short Ratio0.23 Perf Half Y82.69%
Book/sh1.18 P/B2.42 EPS next Y-16.50% ROA-61.00% Target Price5.50 Perf Year-30.15%
Cash/sh0.69 P/C4.16 EPS next 5Y1.00% ROE-80.90% 52W Range0.71 - 6.00 Perf YTD137.50%
Dividend- P/FCF- EPS past 5Y-46.40% ROI-113.30% 52W High-52.50% Beta1.51
Dividend %- Quick Ratio3.50 Sales past 5Y-30.30% Gross Margin- 52W Low301.97% ATR0.34
Employees400 Current Ratio3.50 Sales Q/Q-53.30% Oper. Margin- RSI (14)44.08 Volatility12.52% 12.64%
OptionableYes Debt/Eq0.00 EPS Q/Q19.30% Profit Margin- Rel Volume0.29 Prev Close2.86
ShortableYes LT Debt/Eq0.00 EarningsFeb 27 BMO Payout- Avg Volume2.03M Price2.85
Recom2.40 SMA20-5.33% SMA50-21.07% SMA20022.92% Volume580,196 Change-0.35%
Aug-02-19Downgrade Guggenheim Buy → Neutral
May-31-19Initiated ROTH Capital Buy
May-30-19Resumed Citigroup Buy
May-07-19Downgrade SVB Leerink Outperform → Mkt Perform $12 → $5
Mar-17-17Initiated Wells Fargo Market Perform
Oct-24-16Downgrade BofA/Merrill Neutral → Underperform
Sep-30-16Initiated Raymond James Outperform $16
Feb-25-16Initiated Citigroup Buy $15
Jun-01-15Initiated Leerink Partners Outperform $24
Jun-01-15Initiated Guggenheim Buy
Jun-01-15Initiated BofA/Merrill Neutral
Mar-20-20 10:40PM  Edited Transcript of ADAP earnings conference call or presentation 27-Feb-20 1:00pm GMT Thomson Reuters StreetEvents -5.42%
Mar-11-20 11:35AM  Passage Bio's IPO tops out at $248.4M after options exercised American City Business Journals
Feb-29-20 08:31AM  Earnings Update: Adaptimmune Therapeutics plc Just Reported And Analysts Are Boosting Their Estimates Simply Wall St.
Feb-27-20 07:30AM  Adaptimmune Reports Fourth Quarter / Full Year 2019 Financial Results and Business Update GlobeNewswire
06:00AM  Adaptimmune Therapeutics Plc to Host Earnings Call ACCESSWIRE
Feb-24-20 03:15PM  After leadership overhaul, Adaptimmune targets first cell therapy product launch American City Business Journals
Feb-20-20 04:00PM  Adaptimmune to Report Full Year / Q4 2019 Financial Results and Business Update on Thursday, February 27, 2020 GlobeNewswire
Feb-18-20 08:00AM  Adaptimmune Announces Appointment of Gavin Wood as Chief Financial Officer GlobeNewswire
Feb-07-20 04:05PM  Adaptimmune Therapeutics plc Announces Full Exercise and Closing of Underwriters Option to Purchase Additional American Depositary Shares GlobeNewswire
Feb-05-20 11:30AM  Has Adaptimmune Therapeutics (ADAP) Outpaced Other Medical Stocks This Year? Zacks +11.39%
Feb-03-20 09:13AM  Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue? Zacks
Jan-24-20 04:30PM  Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares GlobeNewswire
Jan-22-20 01:18PM  Philadelphia cell therapy company prices $84M public stock offering American City Business Journals
08:48AM  Adaptimmune Therapeutics plc Prices Public Offering of American Depositary Shares GlobeNewswire
08:25AM  The Daily Biotech Pulse: Johnson & Johnson Earnings, FDA Nod For Horizon Therapeutics, Slew Of Secondary Offerings Benzinga
06:48AM  Top Ranked Momentum Stocks to Buy for January 22nd Zacks
Jan-21-20 04:08PM  Adaptimmune Therapeutics plc Proposes Public Offering of American Depositary Shares GlobeNewswire -8.41%
Jan-17-20 12:00PM  What Makes Adaptimmune Therapeutics PLC (ADAP) a New Buy Stock Zacks
Jan-15-20 08:22AM  The Daily Biotech Pulse: Nektar Withdraws Opioid Pain Drug NDA, Galapagos Takes Stake In Fibrocor, Integra Lifesciences Lowers Q4 Guidance Benzinga +9.90%
Jan-14-20 12:29PM  After a Massive Gain, Is There Still Room for Adaptimmune (ADAP) Stock to Soar? TipRanks
07:55AM  The Daily Biotech Pulse: PhaseBio To Buy Hypertension Asset, Stemline Falls On Q4 Pre-Announcement, FDA Panel To Review Nektar's Opioid Drug Benzinga
02:08AM  Astellas and Adaptimmune Enter into Agreement to Co-Develop and Co-Commercialize Stem-Cell Derived Allogeneic CAR-T and TCR T-Cell Therapies GlobeNewswire
Jan-13-20 08:30AM  Adaptimmune Appoints Elliot Norry as Chief Medical Officer and Makes Changes to R&D Leadership GlobeNewswire +200.00%
02:00AM  Adaptimmune Announces that SPEAR T-cell Platform Delivers Initial Responses in Four Solid Tumor Indications GlobeNewswire
Dec-30-19 05:25AM  Adaptimmune Therapeutics (NASDAQ:ADAP) Will Have To Spend Its Cash Wisely Simply Wall St. -15.94%
Dec-16-19 05:45AM  Is Adaptimmune Therapeutics plc (ADAP) Going To Burn These Hedge Funds ? Insider Monkey +9.02%
Dec-03-19 02:20PM  Adaptimmune gets FDA designation to accelerate development of cancer therapy American City Business Journals +5.88%
08:30AM  Regenerative Medicine Advanced Therapy Designation Granted by FDA to ADPA2M4 for the Treatment of Synovial Sarcoma GlobeNewswire
Nov-17-19 11:40AM  Edited Transcript of ADAP earnings conference call or presentation 6-Nov-19 1:00pm GMT Thomson Reuters StreetEvents
Nov-16-19 02:00AM  Updated Data from Phase 1 ADP-A2M4 Trial Demonstrating Continued Clinical Benefit for People with Synovial Sarcoma GlobeNewswire
Nov-06-19 07:30AM  Adaptimmune Reports Third Quarter 2019 Financial Results and Business Update GlobeNewswire -16.35%
Nov-01-19 08:00AM  Adaptimmune to Report Third Quarter 2019 Financial Results and Business Update on Wednesday, November 6, 2019 GlobeNewswire +9.10%
Oct-31-19 01:52PM  Is Adaptimmune Therapeutics plc (ADAP) Is Burning These Hedge Funds Insider Monkey
06:09AM  Do Directors Own Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares? Simply Wall St.
Oct-09-19 08:00AM  Adaptimmune and Cryoport Announce Agreement to Ensure Safe and Fully Monitored Transport of Adaptimmunes Cell Therapies GlobeNewswire +6.93%
Oct-01-19 08:00AM  Adaptimmune Announces Appointment of Michael Garone as Interim Chief Financial Officer GlobeNewswire -5.30%
Sep-30-19 08:45AM  Clear Benefit for Patients with Synovial Sarcoma Demonstrated in Updated Data from Ongoing Phase 1 Trial with ADP-A2M4 Presented at ESMO GlobeNewswire
Sep-16-19 06:41AM  Does The Adaptimmune Therapeutics plc (NASDAQ:ADAP) Share Price Fall With The Market? Simply Wall St.
Sep-10-19 09:01AM  Adaptimmune (ADAP) Gets Orphan Drug Status for T-cell Therapy Zacks +24.12%
Sep-09-19 08:00AM  United States Orphan Drug Designation for Treatment of Soft Tissue Sarcomas Granted to SPEAR T-cells Targeting MAGE-A4 GlobeNewswire +8.28%
Aug-27-19 02:11PM  Edited Transcript of ADAP earnings conference call or presentation 1-Aug-19 12:00pm GMT Thomson Reuters StreetEvents +6.99%
08:00AM  Adaptimmune and Noile-Immune Announce Agreement to Develop SPEAR T-Cell Products expressing IL-7 and CCL19 as a next-generation treatment for cancer patients GlobeNewswire
Aug-16-19 11:23AM  What's in Store for Aytu BioScience's (AYTU) Q4 Earnings? Zacks +11.64%
Aug-01-19 10:24PM  Adaptimmune Therapeutics (ADAP) Q2 2019 Earnings Call Transcript Motley Fool -10.33%
07:15AM  New Executive Team Announced at Adaptimmune GlobeNewswire
07:15AM  Adaptimmune Reports Second Quarter 2019 Financial Results and Business Update GlobeNewswire
Jul-29-19 04:05PM  Adaptimmune to Report Second Quarter 2019 Financial Results and Business Update on Thursday, August 1, 2019 GlobeNewswire
Jul-25-19 08:00AM  Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS GlobeNewswire -9.06%
Jul-22-19 08:00AM  Adaptimmune Has Initiated a Radiation Sub-Study to Enhance Antitumor Activity Seen With ADP-A2M4 in Collaboration with The MD Anderson Cancer Center GlobeNewswire +11.62%
Jul-18-19 11:00AM  How Should Investors Feel About Adaptimmune Therapeutics plc's (NASDAQ:ADAP) CEO Pay? Simply Wall St.
08:00AM  Adaptimmune Starts the SURPASS Clinical Trial with its first Next-Generation SPEAR T-cells Targeting MAGEA4 to Enhance Antitumor Responses GlobeNewswire
Jul-09-19 11:23AM  Athenex (ATNX) in Focus: Stock Moves 6.5% Higher Zacks
09:00AM  Adaptimmune Therapeutics PLC (ADAP) Upgraded to Strong Buy: Here's Why Zacks
Jun-29-19 05:37PM  Is Adaptimmune Therapeutics plc (ADAP) Going to Burn These Hedge Funds? Insider Monkey
Jun-27-19 02:54PM  Hedge Funds Piled Into This Stock Right Before Its 40% Ascend Insider Monkey
08:00AM  Adrian Rawcliffe to Succeed James Noble as Adaptimmune Chief Executive Officer GlobeNewswire
May-28-19 10:14AM  Those Who Purchased Adaptimmune Therapeutics (NASDAQ:ADAP) Shares A Year Ago Have A 72% Loss To Show For It Simply Wall St.
May-15-19 12:28PM  AdaptImmune partners to advance promising cancer immunotherapies American City Business Journals
08:00AM  Adaptimmune and Alpine Immune Sciences Announce Collaboration and License Agreement to Develop Next-Generation SPEAR T-Cell Products GlobeNewswire
May-06-19 07:30AM  Adaptimmune Reports First Quarter 2019 Financial Results GlobeNewswire -5.82%
07:00AM  Significant Clinical Progress as Adaptimmune Announces Responses with ADP-A2M4 in Synovial Sarcoma and Antitumor Activity in Other Solid Tumors GlobeNewswire
May-02-19 07:00AM  Adaptimmune to Present Data Demonstrating that its Off-the-shelf Process Produces T-cells from Stem Cells that Respond to Cancer Targets with a SPEAR TCR at ASGCT Meeting GlobeNewswire
May-01-19 08:00AM  Adaptimmune to Provide Clinical and Business Update on Monday May 6th, 2019 GlobeNewswire
Apr-18-19 04:01PM  Adaptimmune Announces Oral Presentation of Allogeneic SPEAR T-cell Program at 2019 ASGCT Meeting GlobeNewswire
Apr-12-19 03:26PM  These 3 Falling Knives Are Expected to Outperform GuruFocus.com
Apr-02-19 08:00AM  Adaptimmune Presents Safety Data with Evidence of Tumor Necrosis in One Patient from ADP-A2AFP Study at American Association for Cancer Research (AACR) Meeting GlobeNewswire +8.29%
Apr-01-19 08:00AM  Adaptimmune Presents Preclinical Data for its Next Generation SPEAR T-cell Targeting MAGE-A4 at the American Association for Cancer Research (AACR) Annual Meeting GlobeNewswire
Mar-15-19 12:06PM  Does Adaptimmune Therapeutics plc (NASDAQ:ADAP) Have A Particularly Volatile Share Price? Simply Wall St.
Mar-06-19 12:15PM  Edited Transcript of ADAP earnings conference call or presentation 27-Feb-19 1:00pm GMT Thomson Reuters StreetEvents -8.66%
Feb-27-19 07:29AM  Adaptimmune Reports Fourth Quarter / Full Year 2018 Financial Results and Business Update GlobeNewswire
Feb-07-19 11:01AM  Should You Worry About Adaptimmune Therapeutics plcs (NASDAQ:ADAP) CEO Salary Level? Simply Wall St.
08:00AM  Adaptimmune to Report Fourth Quarter / Full Year 2018 Financial Results and Business Update on Wednesday, February 27, 2019 GlobeNewswire
Jan-28-19 09:38AM  Adaptimmune Therapeutics PLC (ADAP) Upgraded to Buy: Here's What You Should Know Zacks
Jan-08-19 04:30PM  Radius Exceeds 2018 Financial Guidance, Provides Updates Zacks
09:54AM  Alnylam (ALNY) Reports Preliminary Onpattro Revenues for Q4 Zacks
Jan-07-19 07:30AM  Dose Escalation in Liver Cancer Study with ADP-A2AFP (AFP) SPEAR T-cells and Moving to Expansion Phase in ADP-A2M10 (MAGE-A10) Lung Cancer Study after Favorable Safety Reviews GlobeNewswire +5.94%
Jan-02-19 10:12AM  What Percentage Of Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares Do Insiders Own? Simply Wall St.
Dec-12-18 08:30AM  Adaptimmune Announces that Gwen Binder will leave in January 2019 GlobeNewswire -8.70%
Nov-28-18 08:30AM  Recent Analysis Shows Bellicum Pharmaceuticals, NetEase, Nice, Match Group, SpartanNash, and Adaptimmune Therapeutics Market Influences Renewed Outlook, Key Drivers of Growth GlobeNewswire
Nov-20-18 07:52AM  Edited Transcript of ADAP earnings conference call or presentation 6-Nov-18 1:00pm GMT Thomson Reuters StreetEvents
Nov-14-18 11:10AM  What You Must Know About Adaptimmune Therapeutics plcs (NASDAQ:ADAP) Financial Strength Simply Wall St. -5.83%
Nov-06-18 07:30AM  Adaptimmune Reports Third Quarter 2018 Financial Results and Business Update GlobeNewswire -8.42%
Oct-25-18 04:30PM  Adaptimmune to Report Third Quarter 2018 Financial Results and Business Update on Tuesday, November 6, 2018 GlobeNewswire
08:53AM  3 Beaten-Down Biotech Stocks: Can They Bounce Back? Motley Fool
07:29AM  Adaptimmune Therapeutics Worldwide Enters Oversold Territory Zacks
Oct-22-18 09:48AM  Adaptimmune's stock tumbles after cancer study results prompts price target cut MarketWatch -29.83%
Oct-20-18 10:45AM  Updated Data from Ongoing MAGE-A10 and MAGE-A4 Studies Presented at the 2018 ESMO Congress GlobeNewswire
Oct-17-18 07:20AM  Investor Expectations to Drive Momentum within Arsanis, Dynavax Technologies, Puma Biotechnology, Opko Health, Adaptimmune Therapeutics, and Codexis Discovering Underlying Factors of Influence GlobeNewswire
Oct-08-18 06:10PM  Data Updates from Ongoing MAGE-A10 Studies and MAGE-A4 Study to be presented at the European Society for Medical Oncology (ESMO) 2018 Congress GlobeNewswire -5.04%
Sep-19-18 07:30AM  3 Biotech Stocks That Big Investors Are Snatching Up Barrons.com
Sep-13-18 09:19AM  Should You Be Holding Adaptimmune Therapeutics plc (NASDAQ:ADAP) Right Now? Simply Wall St.
Sep-07-18 01:14PM  Adaptimmune Therapeutics plc Announces Closing of Registered Direct Offering of American Depositary Shares GlobeNewswire
Sep-05-18 07:30AM  Adaptimmune Therapeutics plc Announces Registered Direct Offering of American Depositary Shares GlobeNewswire
Aug-24-18 10:37AM  Options Traders Expect Huge Moves in Adaptimmune (ADAP) Stock Zacks +11.05%
Aug-20-18 08:30AM  Investor Expectations to Drive Momentum within NEXEO SOLUTIONS, Altisource Portfolio Solutions S.A, Celestica, Star Bulk Carriers, Criteo S.A, and Adaptimmune Therapeutics Discovering Underlying Factors of Influence GlobeNewswire
Aug-15-18 07:30AM  Third Dosing Cohort to be initiated in MAGE-A4 SPEAR T-cell Basket Study After Favorable Review of Safety from One Billion Cell Dose Cohort GlobeNewswire
05:34AM  Edited Transcript of ADAP earnings conference call or presentation 2-Aug-18 12:00pm GMT Thomson Reuters StreetEvents
Aug-02-18 07:30AM  Adaptimmune Reports Second Quarter 2018 Financial Results and Business Update GlobeNewswire
06:00AM  Adaptimmune Therapeutics PLC Sponsored ADR to Host Earnings Call ACCESSWIRE
Jul-26-18 01:18PM  Adaptimmune to Report Second Quarter 2018 Financial Results and Business Update on Thursday August 2, 2018 GlobeNewswire
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma. The company has a strategic collaboration and license agreement with GSK to research, develop, and commercialize NY-ESO T-cell therapy; and collaboration agreement with Noile-Immune Biotech Inc. to develop SPEAR T-cells in combination with Noile-Immune's PRIME technology. It also has a co-development and co-commercialization agreement with Universal Cells, Inc to bring new stem-cell derived allogeneic T-Cell therapies to people with cancer. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Sonsini Peter W.10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:55 PM
SANDELL SCOTT D10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:54 PM
Florence Anthony A. Jr.10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:52 PM
MOTT DAVID MDirectorJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:53 PM
BASKETT FOREST10% OwnerJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:51 PM
Behbahani AliDirectorJan 24Buy0.677,500,0005,000,25019,500,000Jan 28 04:52 PM
Norry ElliotChief Medical OfficerJan 14Sale5.139114,6781,326Jan 15 08:03 PM
Bertrand William C JRChief Operating OfficerJan 14Sale5.132,39712,3083,605Jan 15 08:03 PM
Rawcliffe AdrianChief Executive OfficerJan 14Sale5.133,23616,6163,166Jan 15 08:01 PM
Lunger JohnChief Patient Supply OfficerJan 14Sale5.131,1445,8741,681Jan 15 08:02 PM
Noble JamesDirectorJan 13Sale4.67300,0001,400,0000Jan 15 08:01 PM
TAYTON-MARTIN HELEN KATRINAChief Business OfficerJan 13Sale4.50100,000450,0000Jan 15 08:02 PM
Rawcliffe AdrianChief Executive OfficerJan 06Sale1.205,9007,0805,804Jan 07 08:00 PM
Bertrand William C JRChief Operating OfficerJan 06Sale1.203,7314,4775,632Jan 07 08:01 PM
Lunger JohnChief Patient Supply OfficerJan 06Sale1.201,1481,3781,677Jan 07 08:01 PM
Amado RafaelPresident, R&DAug 06Sale2.0611,04322,74917,237Aug 07 09:00 PM
Noble JamesChief Executive OfficerMay 16Option Exercise0.141,773,100253,5531,773,100May 17 06:00 PM
open in yahoo | open in reuters | open in google